ArticleFrontiers in oncology2021

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report.

Tian Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.